Syed E. Abidi

Syed E. Abidi

Voorzitter bij Pharmaceutics International, Inc.

Consumer Services
Health Technology
Industrial Services

Profiel

Syed E.
Abidi
is currently the Chairman at Vensun Pharmaceuticals, Inc. and the Executive Chairman at Pharmaceutics International, Inc. He previously worked as the Director-Pharmaceutics at Hercon Laboratories Corp., Assistant Professor at Duquesne University of The Holy Spirit, Research Assistant at the University of Mississippi, Research Associate at West Virginia University, and Senior Scientist at Schering-Plough Pharmaceuticals.
He also held positions as Principal at Applied Analysis Corp.
and Vice President at American Drug Development, Inc. Dr. Abidi obtained his graduate degree from the University of Mississippi in 1977 and his undergraduate degree from the University of Karachi in 1975.

Actieve functies van Syed E. Abidi

BedrijvenFunctieBegin
Voorzitter 06-09-2016
Voorzitter -
Alle actieve functies van Syed E. Abidi

Eerdere bekende functies van Syed E. Abidi

BedrijvenFunctieEinde
American Drug Development, Inc. Corporate Officer/Principal 01-01-1995
Corporate Officer/Principal 01-01-1990
University of Mississippi Corporate Officer/Principal -
West Virginia University Corporate Officer/Principal -
Duquesne University of The Holy Spirit Corporate Officer/Principal -
Ervaring van Syed E. Abidi in detail bekijken

Opleiding van Syed E. Abidi

University of Mississippi Graduate Degree
University of Karachi Undergraduate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Syed E. Abidi in detail bekijken

Connecties

50

Eerstegraads connecties

10

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit5

Health Technology

Hercon Laboratories Corp.

Schering-Plough Pharmaceuticals

Industrial Services

Health Technology

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Syed E. Abidi
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU